Sermorelin powder-also referred to as GHRH (1-29) or GRF(1-29)-is the N-terminal 29-amino-acid fragment of human growth hormone–releasing hormone, typically supplied as the acetate salt in a white lyophilized powder. It selectively acts on GHRH receptors in the anterior pituitary, engaging the cAMP/PKA pathway to promote pulsatile GH secretion and upstream modulation of the IGF-1 axis. Unlike the GHRP class/ghrelin-receptor agonists, it targets a different receptor and signaling route, which helps researchers differentiate mechanisms in experimental design.
The product is available as bulk raw material or pre-filled lyophilized vials and is suitable for cell studies, early-stage animal research, and method development. Upon request, we provide additional testing services including purity, peptide content, endotoxin, and residual solvents. As a sermorelin manufacturer, Medibridge Biotech supports bulk wholesale, flexible mg-per-vial customization, label/box options, and ready-to-ship inventory to shorten lead times.
For current promotions or direct factory sourcing of research peptides, contact us for details.
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
Sermorelin |
86168-78-7 |
MB2510091630 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2025-10-09 |
2025-10-10 |
2027-10-08 |
|
Sample Qty Base |
Packing |
Test Method |
|
30.11 KGS |
100GS/ BOTTLE |
HPLC |
|
Item |
Standard |
Results |
|
Purity |
≥98% |
99.17% |
|
Peptide Assay |
≥80% |
91.80% |
|
Mass Spectrum |
3357.93 |
3357.93 |
|
Solubility |
Soluble in water |
Complies |
|
Clarity and color of solution |
Clear and colorless |
Complies |
|
salt |
<5.0% |
1.34% |
|
Water |
≤7.0% |
1.85% |
|
Residual Solvent: Methanol |
||
|
≤0.3% |
0.0107% |
|
|
Acetonitrile |
≤0.041% |
0.021% |
|
Methylene Chloride |
≤0.06% |
0.040% |
|
N,N-Dimethylformamide |
≤0.088% |
N.D. |
|
Triethylamine |
≤0.032% |
N.D. |
|
Tert-butyl methyl ether |
≤0.5% |
0.249% |
|
Endotoxin |
≤0.5 EU/mg |
Complies |
|
Microbial Limit |
Total aerobic bacteria <100 CFU/g Total yeast & mold <50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Storage |
Keep in dark and cool dry place (-20 to 8°C) |
|
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Specifications (for research use only)
|
Form |
Sample Order |
Specification |
|
Raw powder |
1 g |
Purity is NLT 99% |
|
Vials |
10 vials |
3ml/5ml/7ml/15ml vials etc. |
Literature Snapshot
Sermorelin powder acts on GHRH receptors in the pituitary, triggering cAMP/PKA signaling and promoting pulsatile growth hormone (GH) release. This leads to increased IGF‑1 production in the liver and activates downstream anabolic pathways. In both cell and animal models, this GH–IGF‑1 axis has been associated with enhanced protein synthesis (e.g., AKT/mTOR), better nitrogen balance, lean mass support, improved fat metabolism, and modulation of bone and cartilage markers such as collagen, ALP, and aggrecan. Some studies also explore GH surges during sleep and how circadian rhythms affect sampling outcomes.
Scientific Visualization
Sermorelin-Driven GH Pathway
Sermorelin activates pituitary GHRH receptors to restore the physiologic pulsatility of growth hormone release, a rhythm essential for downstream IGF-1 regulation, tissue repair, and metabolic balance. Experimental studies show that pulsatile GH better supports protein synthesis, lipolysis, and insulin sensitivity than continuous exposure. This model allows researchers to track cAMP–GH–IGF-1 dynamics across circadian cycles and sampling intervals.
Pharmacokinetic–Pharmacodynamic (PK–PD) Insights
Preclinical studies describe Sermorelin as a short-acting GHRH analog with rapid plasma clearance but strong pharmacodynamic coupling to GH pulses. Peak GH release typically occurs within 15–30 minutes post-administration, followed by a secondary rise in hepatic IGF-1 within several hours. The transient PK profile allows for precise time-series sampling, making it ideal for modeling GH/IGF-1 feedback and pulsatility dynamics. Comparative PK–PD analyses with longer GHRH analogs, such as Tesamorelin, confirm that Sermorelin produces sharper GH peaks and faster normalization, supporting its use in mechanistic and circadian-phase studies.
Sermorelin vs Tesamorelin vs GHRP3
Emerging Research Directions
Targets GHRH receptors in the anterior pituitary. Activates the cAMP/PKA signaling pathway. Promotes pulsatile GH secretion. Mimics natural GH rhythms. Used in research,GH deficiency models, and anti-aging studies. Functional core fragment of endogenous GHRH.Emphasizes physiological exposure.
Also binds to GHRH receptors, but with enhanced stability. Activates the same cAMP/PKA pathway. Elevates IGF- 1 levels and improves lipid metabolism. Approved for HIV-related lipodystrophy in some regions. Suitable for clinical applications. Longer half-life and greater receptor affinity than. Sermorelin.Often used in therapeutic and translational research.
Activates the PLC一 Ca²+ signaling pathway. Stimulates GH secretion via a distinct mechanism. Supports bone turnover and cartilage regeneration. Commonly used in metabolic and tissue repair studies .Can be combined with Sermorelin for synergistic effects Independent of the GHRH pathway.
FAQ
Q: Does Sermorelin reduce belly fat?
A: While not a direct lipolytic agent, Sermorelin's stimulation of GH and IGF‑1 can influence lipid metabolism in research models. Studies show improved fat oxidation and lean mass markers, but effects are model-, dose-, and schedule-dependent. It is not a weight-loss drug and should be interpreted within mechanistic frameworks.
Q: Who should avoid peptides?
A: In research, exclusion criteria may include models with disrupted GH axis, pituitary lesions, or altered receptor expression. For translational relevance, studies often avoid confounding variables like concurrent hormone therapies or metabolic disorders.
Q: Can Sermorelin be used to model age-related decline in GH secretion?
A: Sermorelin is frequently used in aging-related endocrine studies to simulate declining hypothalamic GHRH output. Its ability to trigger physiologic GH pulses makes it ideal for assessing pituitary responsiveness, IGF‑1 feedback, and anabolic resistance in aged models.
Q: How quickly does Sermorelin work?
A: Sermorelin induces GH release within minutes of administration, with peak serum GH levels typically observed around 15–30 minutes post-injection. This rapid onset makes it ideal for studying pulsatile GH kinetics, time-sensitive sampling, and short-term feedback loops in endocrine models.
Q: Are peptides hard on your liver?
A: Sermorelin itself is not hepatotoxic in standard research doses. In fact, it stimulates hepatic IGF‑1 production. However, liver function should be monitored in long-term studies, especially when combined with other metabolic modulators or in disease models.
Q: What sampling strategy is optimal for tracking GH pulses after Sermorelin administration?
A: Due to the rapid and transient nature of GH release, frequent sampling (e.g., every 10–20 minutes over 2–3 hours) is recommended to capture peak amplitude and pulse frequency. Time-course ELISA or multiplex assays are commonly used to quantify GH and IGF‑1 dynamics.
Sermorelin powder currently shows strong promise in studies of growth hormone physiology, IGF-1 regulation, and metabolic modulation in laboratory settings. If you are looking for a high-quality peptide manufacturer committed to building a long-term and stable partnership, please contact us at: hi@medibridgeapi.com.
Hot Tags: sermorelin powder, China sermorelin powder manufacturers, suppliers, factory, BPC 157 Powder, Survodutide Peptide, Ghrp Peptide, Selank Powder, Peptide SS 31, Thymosin Alpha 1 Peptide
